Ayati Devices funding marks a significant milestone for Indian MedTech: the Bengaluru-based startup has raised ₹15 crore (approximately $1.5 million) in a Pre-Series A round led by Inflexor Ventures, as publicly reported on 2026-08-11. The round is the company’s first institutional investment, signalling growing investor conviction in point-of-care diagnostics for diabetic foot care. Ayati Devices develops portable, clinically accurate diagnostic technologies aimed at making preventive screening accessible well beyond tertiary hospitals.
Quick Highlights
- Founder & CEO: Nishant Kathpal
- Lead Investor: Inflexor Ventures
- Investor Background: Inflexor Ventures is a technology-focused early-stage venture capital firm investing from seed to Series A+ stages across healthtech, fintech, deep-tech, and other sectors in India
- Headquarters: Bengaluru, Karnataka
- Founded: 2019
- Incubation: IIT Bombay’s Society for Innovation and Entrepreneurship (SINE)
- Announcement Date: 11 August 2026
Funding Breakdown
Use of Funds
As publicly reported, the fresh capital will accelerate commercialisation of Ayati Devices’ next-generation diagnostic technologies, expand its presence in domestic and international markets, and strengthen manufacturing capabilities. The company will also deepen investments in research, regulatory approvals, artificial intelligence, and global talent. Additionally, Ayati Devices plans to expand its pay-per-test screening model — the PODIA Trolley — across hospitals, primary care clinics, and community programmes, making preventive diagnostics more financially accessible for healthcare providers.
Funding Timeline
This Pre-Series A raise of ₹15 crore is Ayati Devices’ first institutional funding round, as publicly reported. No prior institutional rounds have been disclosed.
Expansion Plans
Ayati Devices intends to grow its footprint across both domestic and international healthcare markets. The company currently reports deployment of more than 10,000 devices across over 30 countries, with clinical deployments at institutions including Medicover Hospital and Aster Hospital. Its technologies have received regulatory clearances across major markets, including CDSCO approval in India, U.S. FDA clearance, and CE Mark in Europe, along with approvals in Sri Lanka, Malaysia, and the UAE. The company will invest in global talent acquisition and plans to advance its product roadmap to reach a broader patient base before diabetic foot complications become irreversible.
Significance
This Ayati Devices funding round matters because it transitions the startup from technology validation into a formal phase of commercial scale — a notoriously difficult leap for hardware-led MedTech companies. The company estimates its total addressable market at around USD 15 billion globally and USD 1.4 billion in India, spanning diabetic neuropathy, peripheral vascular disease, and tissue perfusion imaging. With over one million screenings completed and a multi-product platform covering the full diabetic foot diagnostic pathway — including Vibrasense, Vibrasense+T, Vasosense, and Angiocam — Ayati Devices is well-positioned to serve primary care settings that have historically lacked access to such specialist tools. Inflexor Ventures’ backing, with its focus on technology-IP-driven startups, further validates Ayati’s proprietary hardware-software integration and growing intellectual property portfolio as a defensible competitive position in global non-invasive diagnostics.
These details have been verified against multiple publicly available reports as of 2026-08-11.
Stay updated with the latest startup funding news on The Courtroom.
Disclaimer: This report is compiled from publicly available sources and is for informational purposes only; funding figures are as publicly reported and may be subject to change.
